MX2018006092A - Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf. - Google Patents
Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.Info
- Publication number
- MX2018006092A MX2018006092A MX2018006092A MX2018006092A MX2018006092A MX 2018006092 A MX2018006092 A MX 2018006092A MX 2018006092 A MX2018006092 A MX 2018006092A MX 2018006092 A MX2018006092 A MX 2018006092A MX 2018006092 A MX2018006092 A MX 2018006092A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf
- antagonist
- pharmaceutical package
- layer
- filled pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M2005/3131—Syringe barrels specially adapted for improving sealing or sliding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un envase farmacéutico precargado que comprende una formulación líquida de un antagonista del VEGF, por ejemplo, Ranibizumab, en un envase farmacéutico precargado, por ejemplo, una jeringa, cartucho o vial, fabricado en parte o en su totalidad con un polímero termoplástico, recubierto en el interior con un recubrimiento o capa de unión, un recubrimiento o capa de barrera, un recubrimiento o capa protectora de pH y opcionalmente un recubrimiento o capa lubricante. Elrendimiento de estabilidad del antagonista del VEGF envasado en el recipiente revestido de COP se obtuvo comparable o mejor que con el vidrio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562257210P | 2015-11-18 | 2015-11-18 | |
PCT/US2016/062767 WO2017087798A1 (en) | 2015-11-18 | 2016-11-18 | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018006092A true MX2018006092A (es) | 2019-01-31 |
Family
ID=57485953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018006092A MX2018006092A (es) | 2015-11-18 | 2016-11-18 | Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf. |
Country Status (12)
Country | Link |
---|---|
US (3) | US10925927B2 (es) |
EP (1) | EP3377100A1 (es) |
JP (1) | JP6882738B2 (es) |
KR (1) | KR102354198B1 (es) |
CN (1) | CN108883172A (es) |
AU (1) | AU2016358111B2 (es) |
BR (1) | BR112018009953B1 (es) |
CA (1) | CA3005117C (es) |
MX (1) | MX2018006092A (es) |
RU (1) | RU2734958C2 (es) |
WO (1) | WO2017087798A1 (es) |
ZA (1) | ZA201803983B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2918419C (en) | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US11654046B2 (en) * | 2015-11-18 | 2023-05-23 | Sio2 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
IL260323B1 (en) | 2015-12-30 | 2024-09-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
ES2960921T3 (es) | 2017-03-27 | 2024-03-07 | Regeneron Pharma | Procedimiento de esterilización |
EP3630062A2 (en) * | 2017-05-24 | 2020-04-08 | SiO2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
AU2018204933B2 (en) * | 2017-07-06 | 2024-08-22 | Plas-Tech Engineering, Inc. | Systems and methods related to fluid pumping |
WO2019020777A1 (en) * | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
CN111132695A (zh) * | 2017-08-18 | 2020-05-08 | 里珍纳龙药品有限公司 | 分析样品基质中蛋白变异体的成像毛细管等电聚焦 |
SG11202004268PA (en) * | 2017-11-30 | 2020-06-29 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
EP3735286A4 (en) | 2018-01-03 | 2021-03-03 | Irenix Medical, Inc. | DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS WITH INTEGRATED PAIN RELIEF, AND THEIR METHODS FOR USE |
WO2019136238A1 (en) * | 2018-01-04 | 2019-07-11 | Advanced Aesthetic Technologies, Inc. | Methods and devices for fracturing a hydrogel prior to delivery through a needle |
US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
JP2021514781A (ja) * | 2018-03-06 | 2021-06-17 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | 低潤滑剤疎水性シリンジバレルを有するメディカルデリバリーデバイス |
US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
US11667702B2 (en) | 2018-03-08 | 2023-06-06 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
CA3099551A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
CN112469457B (zh) * | 2018-07-31 | 2023-02-28 | 日本瑞翁株式会社 | 预充式注射器和预充式注射器的制造方法 |
EP3831429A4 (en) * | 2018-07-31 | 2021-12-29 | Zeon Corporation | Pre-filled syringe and pre-filled syringe production method |
DE102018122001A1 (de) * | 2018-09-10 | 2020-03-12 | Schott Ag | Packmittel mit Gleitschicht und Verfahren für pharmazeutische und kosmetische Stoffe und Zubereitung zu dessen Herstellung |
WO2020092373A1 (en) * | 2018-10-29 | 2020-05-07 | Sio2 Medical Products, Inc. | Primary containers with improved protein drug stability and lower immune response |
CA3127768A1 (en) * | 2019-01-25 | 2020-07-30 | Sio2 Medical Products, Inc. | Common contact surfaces for use in the manufacture, packaging, delivery, and assessment of biopharmaceutical products |
US20220143137A1 (en) * | 2019-02-13 | 2022-05-12 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
TW202123988A (zh) | 2019-09-03 | 2021-07-01 | 美商安進公司 | 用於藥物遞送之注入裝置及用於注入裝置之包裝物 |
WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
IL302538A (en) | 2019-12-06 | 2023-07-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
US20230355757A1 (en) * | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
US20240316281A1 (en) * | 2021-04-06 | 2024-09-26 | Vitrean Inc. | A prefilled syringe containing a sterile ultraconcentrated hydrogel |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294695A (en) | 1974-01-14 | 1981-10-13 | Standard Oil Company | Multi-phase separation methods and apparatus |
DE2629557B2 (de) | 1976-07-01 | 1980-05-14 | Paul E. Dr.Med. 8000 Muenchen Doerr | Einmai-Injektionsspritze |
NL8102178A (nl) | 1981-05-02 | 1982-12-01 | Stichting Centraal Lab | Werkwijze voor het aantonen van tegen bepaalde antigenen gerichte antistoffen, alsmede inrichting en reagentia voor het uitvoeren van deze werkwijze. |
US4424057A (en) | 1982-04-01 | 1984-01-03 | House Hugh A | Wet-dry syringe |
JPH034282Y2 (es) | 1986-09-16 | 1991-02-04 | ||
US4820278A (en) | 1988-01-13 | 1989-04-11 | The Boeing Company | Non-contaminating renewable syringe |
ES2024564B3 (es) | 1988-02-16 | 1992-03-01 | Arzneimittel Gmbh Apotheker Vetter & Co Ravensburg | Jeringuilla con fines medicinales |
DE3916101A1 (de) | 1989-05-17 | 1990-11-22 | Vetter & Co Apotheker | Spritze fuer medizinische zwecke |
US4986820A (en) | 1989-06-23 | 1991-01-22 | Ultradent Products, Inc. | Syringe apparatus having improved plunger |
US6124449A (en) | 1990-06-11 | 2000-09-26 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US5731144A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
DE9321547U1 (de) | 1993-05-06 | 1999-07-15 | Becton Dickinson And Co., Franklin Lakes, N.J. | Spritze für medzinische Zwecke |
DE4331137A1 (de) | 1993-05-06 | 1994-11-10 | Becton Dickinson Co | Spritze für medizinische Zwecke |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
US5607399A (en) | 1995-09-22 | 1997-03-04 | Becton, Dickinson And Company | Backstop device for a flangeless syringe |
BRPI9809388B8 (pt) | 1997-04-07 | 2021-05-25 | Genentech Inc | anticorpos humanizados e métodos para a formação de anticorpos humanizados. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
NZ500078A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
MEP3208A (xx) | 1999-06-08 | 2010-02-10 | Regeneron Pharma | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
KR20050047118A (ko) | 2002-09-18 | 2005-05-19 | 알러간, 인코포레이티드 | 안과 임플란트의 수송을 위한 방법 및 장치 |
US7431989B2 (en) | 2003-05-06 | 2008-10-07 | Tribofilm Research, Inc. | Article with lubricated surface and method |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
JP4430903B2 (ja) * | 2003-08-29 | 2010-03-10 | テルモ株式会社 | グリチルリチン酸水溶液充填プレフィルドシリンジ |
EP3753548A1 (en) * | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
DE102006048658B4 (de) | 2006-10-14 | 2014-03-27 | Khs Corpoplast Gmbh | PICVD-Beschichtung für Kunststoffbehälter und Verfahren zu deren Herstellung |
US20080228147A1 (en) | 2007-03-15 | 2008-09-18 | Bristol-Myers Squibb Company | Injector for use with pre-filled syringes and method of assembly |
US8529521B2 (en) | 2007-04-23 | 2013-09-10 | Ultimed Inc. | Low-dosage syringe |
JP2011519347A (ja) | 2008-02-07 | 2011-07-07 | アムジエン・インコーポレーテツド | 安定化されたタンパク質組成物 |
EP3216803B1 (en) | 2008-06-25 | 2020-03-11 | Novartis Ag | Stable and soluble antibodies inhibiting vegf |
RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
US8322577B2 (en) | 2009-04-24 | 2012-12-04 | Agilent Technologies, Inc. | Syringe with improved plunger |
US7985188B2 (en) | 2009-05-13 | 2011-07-26 | Cv Holdings Llc | Vessel, coating, inspection and processing apparatus |
DK2251454T3 (da) | 2009-05-13 | 2014-10-13 | Sio2 Medical Products Inc | Coating og inspektion af beholder |
DE102009023335A1 (de) | 2009-05-29 | 2010-12-02 | Lts Lohmann Therapie-Systeme Ag | Zweikammer Zylinder-Kolben-Einheit zur Lyophilisation, Lagerung, Rekonstitution und Applikation von Injektionslösungen für einen Injektor und Verfahren zum Befüllen der Zylinder-Kolben-Einheit |
US8530536B2 (en) * | 2009-10-01 | 2013-09-10 | Momentive Performance Materials Inc. | Self-lubricating pharmaceutical syringe stoppers |
WO2011090717A1 (en) | 2009-12-28 | 2011-07-28 | Gvd Corporation | Coating methods, systems, and related articles |
WO2011117878A1 (en) | 2010-03-20 | 2011-09-29 | Pawan Trilokchand Agrawal | Plastic pre-filled syringe |
TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
US11707408B2 (en) | 2011-10-25 | 2023-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
JP2013116289A (ja) | 2011-12-05 | 2013-06-13 | Daikyo Seiko Ltd | 医薬品用注射器 |
AU2013100071C4 (en) | 2012-07-03 | 2013-05-02 | Novartis Ag | Device |
JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
WO2014052792A1 (en) * | 2012-09-28 | 2014-04-03 | Sio2 Medical Products, Inc. | Halogenated or parylene polymer coating |
WO2014085348A2 (en) | 2012-11-30 | 2014-06-05 | Sio2 Medical Products, Inc. | Controlling the uniformity of pecvd deposition on medical syringes, cartridges, and the like |
KR102211788B1 (ko) * | 2013-03-11 | 2021-02-04 | 에스아이오2 메디컬 프로덕츠, 인크. | 코팅된 패키징 |
US9863042B2 (en) | 2013-03-15 | 2018-01-09 | Sio2 Medical Products, Inc. | PECVD lubricity vessel coating, coating process and apparatus providing different power levels in two phases |
CA2926710A1 (en) * | 2013-10-07 | 2015-04-16 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
WO2015071348A1 (en) | 2013-11-18 | 2015-05-21 | Formycon Ag | Pharmaceutical composition of an anti-vegf antibody |
KR20170003973A (ko) * | 2014-05-12 | 2017-01-10 | 포르미콘 아게 | Vegf 안타고니스트를 포함하는 사전충전형 플라스틱제 주사기 |
WO2018123276A1 (ja) | 2016-12-27 | 2018-07-05 | テルモ株式会社 | コーティング剤および当該コーティング剤で表面処理してなる医療機器 |
-
2016
- 2016-11-18 MX MX2018006092A patent/MX2018006092A/es unknown
- 2016-11-18 CA CA3005117A patent/CA3005117C/en active Active
- 2016-11-18 EP EP16806413.7A patent/EP3377100A1/en active Pending
- 2016-11-18 WO PCT/US2016/062767 patent/WO2017087798A1/en active Application Filing
- 2016-11-18 JP JP2018525414A patent/JP6882738B2/ja active Active
- 2016-11-18 RU RU2018120377A patent/RU2734958C2/ru active
- 2016-11-18 BR BR112018009953-8A patent/BR112018009953B1/pt active IP Right Grant
- 2016-11-18 US US15/777,276 patent/US10925927B2/en active Active
- 2016-11-18 KR KR1020187016506A patent/KR102354198B1/ko active IP Right Grant
- 2016-11-18 AU AU2016358111A patent/AU2016358111B2/en active Active
- 2016-11-18 CN CN201680076507.2A patent/CN108883172A/zh active Pending
-
2018
- 2018-06-14 ZA ZA201803983A patent/ZA201803983B/en unknown
-
2021
- 2021-01-21 US US17/154,702 patent/US11298405B2/en active Active
-
2022
- 2022-02-26 US US17/681,730 patent/US11666632B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112018009953A8 (pt) | 2019-02-26 |
RU2018120377A3 (es) | 2020-03-19 |
CA3005117A1 (en) | 2017-05-26 |
US20220175883A1 (en) | 2022-06-09 |
WO2017087798A1 (en) | 2017-05-26 |
JP2018537170A (ja) | 2018-12-20 |
US20210220435A1 (en) | 2021-07-22 |
US20190000919A1 (en) | 2019-01-03 |
US11298405B2 (en) | 2022-04-12 |
BR112018009953A2 (pt) | 2018-11-06 |
AU2016358111A1 (en) | 2018-05-17 |
BR112018009953B1 (pt) | 2024-03-05 |
JP6882738B2 (ja) | 2021-06-02 |
EP3377100A1 (en) | 2018-09-26 |
US11666632B2 (en) | 2023-06-06 |
KR20180111774A (ko) | 2018-10-11 |
ZA201803983B (en) | 2020-11-25 |
US10925927B2 (en) | 2021-02-23 |
AU2016358111B2 (en) | 2021-11-18 |
CN108883172A (zh) | 2018-11-23 |
RU2018120377A (ru) | 2019-12-18 |
RU2734958C2 (ru) | 2020-10-26 |
KR102354198B1 (ko) | 2022-01-20 |
CA3005117C (en) | 2023-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018006092A (es) | Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf. | |
MX2018006139A (es) | Envase farmaceutico para formulaciones oftalmicas. | |
BR112017022417A2 (pt) | recipientes anaeróbicos para armazenamento de sangue | |
BR112017028386A2 (pt) | película ou lâmina de barreira, material de acondicionamento laminado, recipiente de acondicionamento, e, método para fabricação de uma película ou lâmina de barreira | |
IL244242B (en) | Connection to the seal for the female fluid route combined with medication containers and medication administration pumps | |
EP3344212A4 (en) | MEDICAL PACK AND DOSAGE PLAN SYSTEM | |
MX2020004735A (es) | Inyector y metodo de montaje. | |
BR112018003865A2 (pt) | película de barreira, material de acondicionamento laminado, e, recipiente de acondicionamento. | |
IL262868B (en) | Fluid transport devices to fill medication pump cartridges with liquid medication | |
AU201611760S (en) | Medication packaging and dispensing container | |
EP3247322A4 (en) | Medication packaging and dose regimen system | |
BR112017009021A2 (pt) | formulação farmacêutica de anticorpo anti-tnfa | |
EP3338839A4 (en) | SYRINGE ASSEMBLY, PRE-FILLED SYRINGE, SEALING CAP FOR EXTERNAL TUBE AND PACKAGING FOR SYRINGE ASSEMBLY | |
MX2017007156A (es) | Producto farmaceutico con estabilidad incrementada que comprende inmunoglobulinas. | |
EP3603602A4 (en) | PACKAGING FOR PRE-FILLED SYRINGE | |
BR112016014870A2 (pt) | Formulação de selante líquido compreendendo monômeros de fibrina e um peptídeo de gprp, seu método de fabricação, recipiente e kit | |
MX2018003089A (es) | Ensamble de vial para medicamento. | |
EP3357525A4 (en) | PACKAGING CONTAINER FOR MEDICAL DEVICE, PACKAGING FOR MEDICAL DEVICE AND CYLINDRICAL PACKING FOR FINISHED SYRINGES | |
BR112016014880A2 (pt) | Composição farmacêutica incluindo palonosetron | |
AU201611757S (en) | Medication packaging and dispensing system | |
GB2528421A (en) | Methods and processes for application of drug delivery polymeric coatings | |
EP3202447A4 (en) | Syringe assembly, pre-filled syringe, seal cap for sheath with puncture needle, and syringe assembly package | |
EP3183187A4 (en) | Medication packaging and dose regimen system | |
IT201600130986A1 (it) | Contenitore in cartone per articoli, quali flaconi/siringhe, contenenti prodotti farmaceutici/cosmetici | |
EP3153195A4 (en) | Syringe cap, needle-mounted syringe, and prefilled syringe formulation |